¿Tienes alguna pregunta?
Email

Technologies

Oncobiomed has the exclusive license to develop and distribute TAPCells.

Cancer represents a serious challenge to public health and the global economy, and its incidence continues to rise. In 2020, more than 19.3 million cases were reported, and this figure is estimated to reach 28.4 million by 2040, driven by population growth and ageing.

Oncobiomed Advanced Cell Technology S.p.A., based in Santiago, Chile, is a biotechnology company specialising in the development and technology transfer of cancer vaccines based on immunogenic lysates.TAPCells® and LycellVax® have been designed as therapies for colon cancer, melanoma, prostate cancer and other types of cancer. These technologies have already completed phase I or phase II clinical trials and have demonstrated superiority over other therapies due to their long-term clinical effectiveness, absence of adverse effects, and adaptation to the economic and social realities of emerging countries. 

The global immunotherapy drug market was estimated at USD 284 billion in 2024 and is expected to reach around USD 1.3 trillion by 2033.In this context, Oncobiomed is valued at USD 32 million, and its technologies are estimated to reach projected sales of USD 6 billion for melanoma and USD 27 billion for prostate cancer.    

The success of the immunotherapies developed by Oncobiomed has benefited more than 300 patients, whose clinical results have been published in scientific journals with global impact. The company has also obtained, logrando además la patents to commercialise its technologies in Chile, Australia, New Zealand, the United States, Mexico, Brazil and Israel..

TapCells®

Immunotherapy based on autologous dendritic cells loaded with immunogenic lysates. Personalized vaccine against skin cancer, prostate cancer and other tumors.

LycellVax®

Immunotherapy based on immunogenic cell lysates. Polyvalent vaccine against solid tumors.

Scientific publications

2020 - 2018
2020
Journal of Immunotherapy of Cancer
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
2019
Journal of Immunology Research

Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell- Dependent Antitumor Immune Responses In Vitro.

2018
Journal of Immunology Research
Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
2018
Oncotarget
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
2018
Cancer immunology, immunotherapy
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
2020
Journal of Immunotherapy of Cancer
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
2019
Journal of Immunology Research

Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell- Dependent Antitumor Immune Responses In Vitro.

2018
Journal of Immunology Research
Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
2018
Oncotarget
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
2018
Cancer immunology, immunotherapy
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
2020
Journal of Immunotherapy of Cancer
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
2019
Journal of Immunology Research

Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell- Dependent Antitumor Immune Responses In Vitro.

2018
Journal of Immunology Research
Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
2018
Oncotarget
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
2018
Cancer immunology, immunotherapy
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.

Contact

Contact

Address
Málaga 85, Las Condes
Santiago, Chile
Phone

+56 9 7753 2325

Email

Please include your phone number or WhatsApp in the message.